MAPT and Alzheimer disease: In 2018, the National Institute on Aging and Alzheimer’s Association (NIA-AA) created an updated research framework for classifying pathological phases of AD based on detection of abnormal levels of molecular biomarkers Aβ (A), tau (T), and neurodegeneration [AT(N)], regardless of cognitive status in living patients (Jack et al., 2018).